olaparib FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo. Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel. Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion Premium The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients. Uterine Leiomyosarcoma Sequences Point to Potentially Targetable Somatic Mutations Using genome, exome, or transcriptome sequences from dozens of uterine leiomyosarcoma samples, researchers found alterations that may respond to existing targetable treatments. Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs. Nov 9, 2020 FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza Jul 31, 2020 Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications Jul 14, 2020 Genetic Alterations in Cyclin-Dependent Kinases Highlight Potential Cancer Treatment Approach May 20, 2020 FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer May 11, 2020 FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer Mar 30, 2020 Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic Feb 11, 2020 Myriad Files sPMA With FDA for Test to ID Best Responders to Lynparza, Avastin Combination Jan 21, 2020 Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer Dec 30, 2019 FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer Aug 7, 2019 Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study Aug 7, 2019 Myriad Genetics Seeking Additional FDA Approval for BRACAnalysis CDx Jul 1, 2019 FDA Approves Foundation Medicine CDx Test for Lynparza Jun 19, 2019 AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan Jun 6, 2019 TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts Premium Jun 3, 2019 Lynparza Delays Progression in Metastatic Pancreatic Cancer Patients With Germline BRCA Mutations Premium May 16, 2019 NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy Premium Apr 4, 2019 Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration Apr 2, 2019 Treatment With Less Toxic Rubraca in Molecularly-Defined Pancreatic Cancer Subset Proposed at AACR Premium Dec 19, 2018 FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting Apr 2, 2018 Japanese Regulators Approve Myriad Genetics' BRACAnalysis Test Load More Breaking News Canadian Healthcare Providers, Policymakers Value Different Aspects of Clinical Genomic Sequencing New Products Posted to GenomeWeb: Oxford Nanopore, Bio-Rad, NanoString, More People in the News at OraSure, Element Biosciences, Micronoma, More Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit In Brief This Week: SQI Diagnostics, T2 Biosystems, Enhanc3D, QuidelOrtho, More Illumina, Precision Health Research Singapore Partner for 100K Genomes Population Study The Scan Blend of Omicron With Delta The Associated Press reports that currently circulating Omicron variants have some features previously seen in the Delta variant. Limited Contrast The New York Times reports that there is a shortage of a contrast agent used for some medical scans. Pig Improvement Farmers in China are using genetics to improve their hog herds, according to Reuters. Science Papers Present Way to Molecularly Classify Prostate Cancer, Saliva-Based SARS-CoV-2 Test, More In Science this week: approach to molecularly classify prostate tumors, saliva-based test for SARS-CoV-2, and more.